AG真人官方

Viking Therapeutics (NASDAQ: VKTX) announced positive top-line results from its Phase 2 VENTURE-Oral Dosing trial of VK2735, an oral tablet formulation targeting obesity treatment. The study achieved both primary and secondary endpoints, demonstrating significant weight loss benefits.

Key highlights include: Up to 12.2% (26.6 lbs) mean weight loss in treated patients compared to 1.3% (2.9 lbs) for placebo after 13 weeks. The trial showed impressive efficacy with up to 97% of subjects achieving 鈮�5% weight loss and up to 80% achieving 鈮�10% weight loss. The drug demonstrated a favorable safety profile with 99% of GI-related adverse events being mild or moderate.

An exploratory maintenance dosing cohort showed promising results, suggesting effective weight maintenance may be achieved at lower doses (30mg) after initial treatment with higher doses.

Gaxos.ai (GXAI) has launched Art-Gen.AI, an advanced AI image and video creation platform targeting the rapidly growing generative AI market. The platform integrates AI models from industry leaders like Google, Stability AI, and PixVerse with Gaxos' proprietary enhancements.

Art-Gen.AI offers a subscription-based model with features including instant image and video generation, smart image transformation, one-click upscaling, dynamic video creation, AI prompt writing, and style presets. The platform aims to streamline content creation for creators, brands, and enterprises while establishing a scalable, high-margin, recurring-revenue model in a market projected to reach hundreds of billions in annual revenue over the next decade.

PainReform (Nasdaq: PRFX) announced that its solar energy business unit, DeepSolar, has been accepted into the prestigious NVIDIA Connect Program. This collaboration will advance DeepSolar Predict, the company's AI-driven solar forecasting solution for photovoltaic systems.

The technology is expected to improve weather forecast accuracy by up to 50% and reduce operational and maintenance costs by up to 30%. DeepSolar Predict aims to help solar asset owners optimize energy sale timing, reduce forecast penalties, and strengthen grid stability through more predictable supply.

The NVIDIA Connect Program provides DeepSolar with access to AI frameworks, development tools, and engineering support, positioning the company to become a key player in performance-driven solar asset management.

SoFi (NASDAQ: SOFI) has announced a partnership with Lightspark to launch blockchain-powered international money transfers through the Bitcoin Lightning Network. The service will enable 24/7 cross-border transfers directly from the SoFi app, offering lower fees compared to traditional remittance providers.

The technology utilizes Universal Money Address (UMA), converting U.S. dollars to Bitcoin in real-time for transfer, then instantly converting back to local currency in the recipient's account. The service will initially launch in Mexico later in 2025, with plans to expand to additional countries. SoFi will be among the first U.S. banks to offer blockchain-powered remittances, integrating the service within SoFi Checking & Savings.

VCI Global (NASDAQ:VCIG) has announced a groundbreaking US$2 billion partnership backed by 18,000 BTC to establish a sovereign-grade infrastructure venture. The company will hold a 70% equity stake in the joint venture, which aims to integrate Bitcoin storage, encrypted AI computing, and real-world asset monetization.

The partnership will leverage VCIG's proprietary QuantVault platform, combining hardware-level encryption, quantum-resilient protocols, and zero-trust architecture. Key initiatives include BTC-backed real-world assets, Vault-as-a-Service, encrypted AI integration, and licensing sovereign reserve systems.

This strategic move positions VCI Global among select Nasdaq-listed companies integrating large-scale Bitcoin reserves with sovereign-grade AI and encrypted infrastructure, as Bitcoin's market cap exceeds US$2.32 trillion with fewer than 2 million BTC remaining to be mined.

TowneBank (NASDAQ: TOWN) has announced a definitive merger agreement to acquire Dogwood State Bank (OTCQX: DSBX) in a strategic expansion move along the Interstate 85 corridor. The transaction, valued at approximately $476.2 million, will be executed through a stock exchange where Dogwood shareholders will receive 0.700 shares of TowneBank stock for each Dogwood share.

Following this acquisition and the pending Old Point Financial Corporation merger, the combined entity will command $22 billion in total assets, $16 billion in loans, and $19 billion in deposits. The merger is expected to be 8.0% accretive to TowneBank's 2027 earnings per share. Dogwood's CEO Steve Jones will join TowneBank as President of North Carolina and South Carolina operations.

Velo3D (NASDAQ:VELO) has announced the pricing of a $17.5 million public offering of common stock and its uplisting to the Nasdaq Capital Market. The company is offering 5,833,333 shares at $3.00 per share, with trading expected to commence on August 19, 2025, under the ticker symbol "VELO".

Lake Street Capital Markets is serving as the sole book-running manager, and the company has granted them a 30-day option to purchase up to 875,000 additional shares. The offering is expected to close around August 20, 2025. The proceeds will be used for working capital, capital expenditures, and general corporate purposes.

KULR Technology Group (NYSE: KULR) has announced strategic partnerships with Molicel and Amprius Technologies (NYSE: AMPX) to launch KULR ONE Air (K1A), an advanced battery system line for unmanned aircraft systems (UAS). The K1A product integrates KULR's thermal management technologies with Amprius' SiCore庐 cylindrical battery cells and Molicel's P50B cells.

Initial sample shipments began in July 2025, with volume production set for Q4 2025. The product line offers both standard and customizable configurations, featuring lightweight lithium-ion chemistries and modular designs for various UAS platforms. The initiative targets the global drone battery market, projected to grow from $9.5 billion in 2025 to $49.6 billion by 2035.

BioXcel Therapeutics (Nasdaq: BTAI) has announced the completion of database lock for its SERENITY At-Home pivotal Phase 3 safety trial, evaluating BXCL501 for acute treatment of agitation in bipolar disorders or schizophrenia patients. The study, conducted across 22 sites nationwide, enrolled over 200 patients and collected data from more than 2,600 agitation episodes.

The trial evaluated a 120 mcg dose of BXCL501 in a double-blind, placebo-controlled study. The company implemented robust oversight controls, including patient eligibility reviews and DSMB reviews. BXCL501 has received Fast Track Designation, addressing an unmet need as there are currently no FDA-approved therapies for acute agitation treatment in at-home settings. Topline results are expected in August.